Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 20Vitamin D Deficiency 17Prostatic Neoplasms 14Neoplasms 9Polycystic Ovary Syndrome 8Colonic Neoplasms 8Rectal Neoplasms 6Colorectal Neoplasms 6Myelodysplastic Syndromes 5Osteoporosis 4Leukemia, Lymphocytic, Chronic, B-Cell 4Cardiovascular Diseases 4Warts 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Brain Neoplasms 3Adenomatous Polyps 3Pathologic Processes 2Pain 2Obesity 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Musculoskeletal Diseases 2Melanoma 2Male Urogenital Diseases 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2

Interventions

Cytarabine 34Filgrastim 14Idarubicin 13Etoposide 12Busulfan 12fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 10Cyclophosphamide 10Mitoxantrone 8Methotrexate 7Daunorubicin 7Cyclosporine 6Tacrolimus 5Radiotherapy 5Clofarabine 5Whole-Body Irradiation 4Mycophenolic Acid 4Gemtuzumab 4Arsenic Trioxide 4Antilymphocyte Serum 4Topotecan 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Decitabine 3eltrombopag 2choline magnesium trisalicylate 2aldesleukin 2Vorinostat 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myelomonocytic, Acute × Cholecalciferol × Clear all
NCT01521936 2015-06-19

Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy

Roswell Park Cancer Institute

Phase 2 Terminated
4 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡